Assessment of nifedipine administration in assisted reproductive technology on the rate of pregnancy
Phase 3
- Conditions
- Infertility.Female infertility
- Registration Number
- IRCT20140111016162N3
- Lead Sponsor
- Tehran University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- Female
- Target Recruitment
- 158
Inclusion Criteria
20-39 years of age
Fresh embryo transfer
Body mass index :18-29
American Society Anesthesiologist physical status classification system I
Exclusion Criteria
History of hypertension
History of hypotension
Abnormal uterine cavity
Contraindication for the use of Estrogen and Progesterone and Nifedipine
Administration of drugs that interact with cytochrome P450 activity including azole antifungals, cimetidine, cyclosporine, erythromycin, quinidine, terfenadine, warfarin, benzodiazepines, flecainide, imipramine, propafenone and theophylline within 3 months prior to study enrollment
Serum follicle-stimulating hormone (FSH) level >20mIU/mL on days 2-4 of the menstrual cycle
Irregular heart beat
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Clinical pregnancy. Timepoint: 4 weeks after embryo transfer. Method of measurement: Ultrasonography.;Chemical pregnancy. Timepoint: 14 days after embryo transfer. Method of measurement: BHCG test.
- Secondary Outcome Measures
Name Time Method Blood pressure Variation. Timepoint: In three intervals including at the time of anesthesia induction, end of anesthesia, and in recovery time. Method of measurement: With a pressure gauge.;Implantation rate. Timepoint: In pregnancy. Method of measurement: The implantation rates will calculated as the number of gestational sacs divided by the number of embryos transferred to the uterus.;Multiple pregnancy rate. Timepoint: After pregnancy. Method of measurement: Ultrasonography.